Detalles de la búsqueda
1.
Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
Br J Haematol
; 204(3): 892-897, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38013238
2.
Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.
Br J Haematol
; 2024 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38811025
3.
Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
Br J Haematol
; 204(4): 1529-1535, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38411250
4.
Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials.
Haematologica
; 108(4): 969-980, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36325893
5.
Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease.
Am J Hematol
; 97(6): 731-739, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35253928
6.
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies.
Mol Ther
; 29(2): 636-644, 2021 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33010231
7.
Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials.
Hematol Oncol
; 39(4): 529-538, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34405901
8.
Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.
Br J Haematol
; 189(5): 920-925, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32020596
9.
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
Br J Haematol
; 191(1): 52-61, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32510599
10.
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Ann Hematol
; 97(5): 923, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29473097
11.
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Ann Hematol
; 97(5): 763-772, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29392425
12.
Repositioning of bromocriptine for treatment of acute myeloid leukemia.
J Transl Med
; 14: 261, 2016 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27604463
13.
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.
Blood
; 121(14): 2734-8, 2013 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-23377436
14.
Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia.
Haematologica
; 105(6): e294-e297, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31537688
15.
Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma.
Cancer Cell Int
; 15: 122, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26696777
16.
Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness.
Br J Haematol
; 185(4): 755-757, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30334573
17.
Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
Ann Hematol
; 93(10): 1695-703, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24824767
18.
Infrequent Presentations of Chronic NPM1-Mutated Myeloid Neoplasms: Clinicopathological Features of Eight Cases from a Single Institution and Review of the Literature.
Cancers (Basel)
; 16(4)2024 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38398096
19.
Refining the diagnosis and prognostic categorization of acute myeloid leukemia patients with an integrated use of cytogenetic and molecular studies.
Acta Haematol
; 129(2): 65-71, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23154527
20.
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8.
Cancers (Basel)
; 15(15)2023 Jul 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37568638